The Servier Judgment: A Breath of Fresh Air for Pharmaceutical Companies?

Dechert LLP

Dechert LLP

On 12 December 2018, the General Court (“Court”) partially annulled the European Commission’s decision of 9 July 2014 in the Servier case and consequently reduced Servier’s fine by more than 30%, from €330.99 million to €228.32 million. After the Lundbeck judgment of 8 September 2016, this second decision on pay for delay cases provides useful guidance to pharmaceutical companies on the assessment of patent settlement agreements under European competition law.

Key Takeaways:

  • When a medicine is not objectively recognized or perceived by practitioners as being superior to other drugs with the same therapeutic indication, the market definition must rely on both a quantitative (price) analysis and qualitative analysis, taking into account a series of factors other than the price such as the therapeutic indications, a comparison of the drugs’ efficacy, doctors’ habits, promotional efforts, etc.
  • The legal consequences of the language contained in internal documents / presentations must be decided in light of other objective factors, such as the conclusions of scientific studies.
  • Non-challenge and non-commercialization clauses included in patent settlement agreements can be justified under competition law unless the generic company is incentivized to accept such clauses in exchange for a reverse payment amounting to a buyout of competition.
  • The combination of a settlement agreement and a license agreement to end a patent dispute is presumed valid insofar as the latter is accessory to the former and generally seen as pro-competitive; it is therefore for the Commission to establish that the level of the royalties does not reflect market conditions.


French pharmaceutical company Servier developed and commercializes Perindopril, a blockbuster indicated for the treatment of cardiovascular diseases, mainly hypertension and heart failure.

Servier’s main patent, covering the API (active pharmaceutical ingredient), was registered in 1981 and expired between 2003 and 2009 depending on the Member States. In the meantime, Servier had filed various other applications for secondary patents covering notably the manufacturing process of the API, including patent No. 947, delivered in 2004.

More than 10 generic companies, which were preparing their market entry or had decided to launch at risk, challenged the validity of patent No. 947 before the European Patent Office (EPO) and certain national courts (in particular in the UK and the Netherlands).

These actions eventually led to several patent settlement agreements between Servier and five generic companies (namely Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin) which had already taken significant steps to develop generic versions of Perindopril and/or had launched at risk. Pursuant to these agreements, the generic companies agreed to refrain from competing with Servier until the expiration of patent No. 947 in exchange for cash settlements totaling €110 million.

In November 2008, in the context of its sector inquiry into the pharmaceutical sector, the European Commission decided to conduct an in-depth review of these settlement agreements. In July 2014, the Commission found that, by significantly delaying the entry of generic versions of Perindopril on the market, these agreements were restrictive of competition under Article 101 of the Treaty on the Functioning of the European Union (“TFEU”). In addition, the Commission found that Servier had implemented a global strategy consisting principally of acquiring any possible technology which was a source of competition, thereby abusing its dominant position on the market for Perindopril, in violation of Article 102 TFEU. Accordingly, the Commission imposed fines on Servier and the five generic companies totaling €427.7 million, including €330.99 million on Servier.

The Court, while confirming the general approach followed by the Commission for assessing the anticompetitive nature of the settlement agreements, partially annulled the latter’s decision on the grounds that it had improperly (i) concluded to the existence of an abuse of dominant position on the part of Servier and (ii) qualified the Krka agreement as pay for delay.

The Court revisits the market definition for Perindopril and consequently annuls the Commission’s findings under Article 102 TFEU

The Court’s judgment constitutes a serious and unexpected setback for the Commission, which faces the annulment of its decision regarding Servier’s sanction for abuse of dominance. Indeed, following an in-depth analysis of the market characteristics, the Court concluded that the Commission had not appropriately delineated the market for Perindopril and that, consequently, Servier could not be regarded as holding a dominant position.

The Commission, consistently with previous practice when competition from generics is at stake, had narrowly defined the market at the level of the Perindopril molecule. The Court, however, concluded that the market, in the present case, was in fact wider and encompassed not only Perindopril and its generics but also all the other drugs classified as ACE inhibitors.

To reach this conclusion, the Court went beyond price competition, which was the focus of the Commission’s analysis. The Court noted that the unique characteristics of the pharmaceutical sector, which is largely influenced by doctors’ choice and less sensitive to price variations, should have led the Commission to carefully analyze the qualitative competitive constraints exerted on Servier by the other ACE inhibitors. In particular, the Court took into account the therapeutic recommendations and publications as well as the therapeutic indications and perceptions by health professionals, none of which pointed to a superiority of Perindopril as compared to other drugs with the same therapeutic indication, especially in terms of efficacy and side effects.

This innovative approach calls for several comments:

  • Firstly, the Court’s approach to market definition contrasts with the view currently prevailing in the U.S. and, so far, in Europe, where functional interchangeability is often seen as secondary and rarely leads to overturn the analysis based on price constraints exerted by generics on originators. The fact that the Court conducted a detailed analysis based on all relevant evidence and resisted the temptation to take an opportunistic approach to market definition had it wished to confirm the existence of an abuse also sends a strong signal to national competition authorities that Article 102 TFEU should be strictly enforced.
  • Secondly, the Court did not take into account the national regulatory constraints in the market definition, although rules on substitution might also create a significant constraint on competition between originators and generics. It thus remains to be seen how national competition authorities will implement the Court’s judgment.
  • Finally, the Court minimized the importance of Servier’s internal documents, on which the Commission partly relied to isolate Perindopril from other ACE inhibitors. The Court interestingly recalls that these documents often have a marketing purpose and thus unsurprisingly tend to promote the unique characteristics of a product rather than necessarily objectively reflecting the actual market conditions. To that extent, the Servier judgment paves the way for future discussions with competition authorities on the interpretation of internal documents and market definition, both with respect to the assessment of anticompetitive practices and mergers.

The Court confirms that pay for delay agreements can qualify as “by object” restrictions of competition under Article 101 TFEU

In 2016, in the Lundbeck judgment, the Court approved the Commission’s treatment of pay for delay agreements as qualifying, under certain conditions, as anticompetitive “by object”, without the need to prove their effective or potential anticompetitive effects. The Court confirms this approach in the Servier judgement.

In particular, it explained that patent settlement agreements containing restrictions such as non-challenge and non-commercialization provisions, although they may pursue a legitimate aim, may be qualified as pay for delay – and hence, as anticompetitive under Article 101 TFEU – when three cumulative conditions are met:

i. the generic company is a potential competitor of the originator;

ii. the generic company, by recognizing the validity of the originator’s patent, agrees to refrain from entering the originator’s market, in exchange for

iii. a disproportionate payment from the originator company, in fact amounting to a buyout of competition.

Firstly, unsurprisingly, the generic manufacturers were all considered as potential competitors of Servier. In that respect, the Court insists on the fact that the mere existence of an intellectual property right cannot be regarded as a legal obstacle to competition, especially in the pharmaceutical sector, where bringing a new product to the market requires several years. In that context, it is not uncommon for generic companies to start taking steps to commercialize their product long before the expiry of the patent, in order to be ready at that stage.

Secondly, regarding the nature of the infringement, the Court’s reasoning is informative and should help companies refine the analysis of their patent settlement agreements.

The Court explained that non-challenge and non-commercialization clauses, which are common in settlement agreements, are, by themselves, restrictive of competition. However, the Court acknowledged that, in the context of a litigation and potential infringement of intellectual property rights, these restrictions in fact serve the same purpose and have the same effects as a court order enforcing the validity of the originator’s patent. Thus, according to the Court, it is not the recognition of the patent validity by the generic companies that rendered the agreements with Servier illegal, but rather the fact that these companies, by accepting a disproportionate reverse payment from Servier, were incentivized to stay out of the market. In other words, what the Court sanctioned is not Servier’s defense of its intellectual property rights, but the buyout of competition through cash settlements.

After scrutiny of all the agreements, the Court concludes that a settlement agreement combined with a license agreement does not constitute a restriction of competition by object

The Court confirmed the restrictive nature of the majority of the settlement agreements concluded between Servier and the generic companies, including those comprising reverse payments but also less traditional terms such as a technology transfer or a supply deal.

However, the Court concluded that the Krka agreement did not amount to pay for delay. More particularly, in 2006, Servier and Krka concluded two agreements:

iv. on the one hand, a settlement agreement pursuant to which Krka agreed to refrain from any activity infringing Servier’s patents; and

v. on the other hand, an exclusive license agreement pursuant to which Krka was granted the right to use, manufacture, promote and sell a generic version of Servier’s Perindopril encompassing the latter’s technology in certain territories.

The Court found that the combination of a patent settlement agreement and a license agreement covering the same patent did not constitute evidence of a reverse payment. On the contrary, the Court noted that the existence of the license agreement could be regarded as ancillary to the settlement agreement insofar as it has the same subject matter. In addition, it implies a payment of royalties from the generic company to the originator, which renders the possibility of a reverse payment less obvious, unless it can be demonstrated that the royalty payment is too low and thus entails a form of compensation. In the present case, the Court concluded that the level of the royalty in the Krka license agreement reflected a negotiation at arm’s length between Krka and Servier.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.